Sandoz

Sandoz Gains Investment-Grade Rating Post Spin-off, Secures Substantial Financing

(IN BRIEF) Novartis has confirmed its plans for a full Spin-off of its Sandoz business, with trading of new Sandoz…

8 months ago

Sandoz Expands Hospital Offering and Anti-Infectives Portfolio with Mycamine® Brand Rights Acquisition

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has successfully acquired the worldwide brand rights for the…

8 months ago

Sandoz’s distribution and collaboration agreement to bring more affordable treatments to the US

(IN BRIEF) Sandoz to commercialize six products exclusively in the US following distribution and collaboration agreement with Adalvo. The products…

1 year ago

Sandoz to Invest Over $400 Million in New Biologics Plant in Slovenia

(IN BRIEF) Sandoz, a global leader in generic and biosimilar medicines, has signed a Memorandum of Understanding to build a…

1 year ago

El CEO de Firmenich, Gilbert Ghostine, encabezará a Sandoz como presidente designado de la nueva junta directiva

(NOTICIA EN BREVE) Gilbert Ghostine ha sido designado presidente designado de la nueva junta directiva de Sandoz, tras el anuncio…

1 year ago

Firmenich CEO Gilbert Ghostine to Lead Sandoz as Chairman-Designate of New Board of Directors

(IN BRIEF) Gilbert Ghostine has been appointed as Chairman-designate of the new Board of Directors of Sandoz, following the announcement…

1 year ago

Sandoz acquires Mycamine, reinforcing its anti-infectives portfolio

(IN BRIEF) Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has signed an agreement to acquire worldwide product…

1 year ago

Sandoz adquiere Mycamine, reforzando su cartera de antiinfecciosos

(NOTICIA EN BREVE) Sandoz, líder mundial en medicamentos sin patente (genéricos y biosimilares), ha firmado un acuerdo para adquirir los…

1 year ago

La división Sandoz de Novartis amplía su cartera de medicamentos respiratorios con la adquisición de la empresa británica Coalesce Product Development Limited

Sandoz obtiene capacidades y activos significativos en el desarrollo de dispositivos médicos y medicamentos que apuntan a importantes oportunidades de…

2 years ago

Novartis division Sandoz expands respiratory medicines portfolio with the acquisition of British company Coalesce Product Development Limited

Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and…

2 years ago

Francesco Balestrieri appointed ad-interim CEO of Sandoz reporting directly to Vas Narasimhan, CEO, Novartis

(PRESS RELEASE) BASEL, 15-Mar-2019 — /EuropaWire/ — Sandoz's current Region Head Europe Francesco Balestrieri has just been appointed ad-interim CEO…

5 years ago

Sandoz certified “TOP Employer Asia Pacific 2019” for its exceptional employee offerings in the region

Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual,…

5 years ago

Sandoz announces European Commission approval for Zessly® (infliximab) for use in Europe

European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars…

6 years ago

Novartis division Sandoz receives US FDA complete response letter regarding the Biologics Licensing Application for its proposed biosimilar rituximab

Holzkirchen, Germany, 04-May-2018 — /EuropaWire/ — Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has…

6 years ago

Sandoz: EMA Committee for Medicinal Products for Human Use (CHMP) adopts positive opinion for marketing authorization of infliximab

Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and…

6 years ago

Sandoz today expands pilot project with leading charity World Child Cancer

Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana…

7 years ago

Generic medicines accounted for 62% of all medicines prescribed in Europe in 2016

New data just released in the two largest global pharma markets show the substantial and growing level of savings made…

7 years ago

Sandoz: European Commission approves Rixathon for use in Europe

European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics…

7 years ago

Novartis Reinforces Commitment to Sandoz With Major Investment in Business

Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global…

7 years ago

New Sandoz Biosimilar Shows Promising Equivalency Results

Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®* Comprehensive…

7 years ago

Sandoz’s EGALITY trial results: equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 met

The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at…

8 years ago

European Medicines Agency accepted Sandoz’s Marketing Authorization Application for biosimilar to Roche’s EU-licensed MabThera®

Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for…

8 years ago

Sandoz and World Child Cancer announce new health initiative in the Philippines

Holzkirchen, Germany, 18-Feb-2016 — /EuropaWire/ — Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a…

8 years ago

Sandoz continues to advance its biosimilars program: US FDA acceptance for its proposed biosimilar pegfilgrastim

Sandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates…

8 years ago

Sandoz announced US market introduction of its generic version of Pulmicort Respules®

Princeton, New Jersey, 30-7-2015 — /EuropaWire/ — Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic…

9 years ago

Sandoz launches respiratory health program aimed at improving the diagnosis and treatment of asthma – Breathe Africa

Non-communicable diseases like asthma are rising rapidly in sub-Saharan Africa where healthcare systems are ill-prepared to cope1 – Zambia is…

9 years ago

Sandoz launches New Life & New Hope program aimed at improving maternal and child health and reduce mortality associated with childbirth in Ethiopia

Approximately 400 mothers and newborns die in Ethiopia each day1,2partly due to health workers’ limited knowledge in the area of…

9 years ago

Sandoz: 160,000 – 200,000 children estimated to be diagnosed with childhood cancer each year

Holzkirchen, Germany, 6-2-2015 — /EuropaWire/ — Between 160,000 and 200,000 children are estimated to be diagnosed with childhood cancer and…

9 years ago

Sandoz announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN®

Pivotal PIONEER study compared safety and efficacy of the two compounds in the prevention of neutropenia in patients with breast…

9 years ago

Global generics industry newsletter Generics Bulletin awarded “Biosimilars Initiative of the Year” to Sandoz

Holzkirchen, 16-10-2014 — /EuropaWire/ — Sandoz is pleased to announce that Generics Bulletin, a newsletter covering commercial and regulatory information for…

10 years ago

Sandoz appoints Vas Narasimhan as Head of Sandoz Biopharmaceuticals & Oncology Injectables

Munich, Germany, 28-3-2014 — /EuropaWire/ — Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals &…

10 years ago

Sandoz announced it received Romanian marketing authorization for AirFluSal® Forspiro®

Holzkirchen, Germany, 31-1-2014 — /EuropaWire/ — Sandoz announced today it has received Romanian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler…

10 years ago

US Federal Circuit Court invalidated patents asserted against Sandoz by Teva Pharmaceuticals in litigation over generic version of Copaxone

Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents…

11 years ago

The global leader in biosimilars Sandoz initiated Phase III clinical trial for biosimilar etanercept

Trial expected to support registration in the U.S. and European Union Sandoz continues to advance biosimilar pipeline with seven Phase…

11 years ago